Review
BMS-561392. Bristol-Myers Squibb
Affiliations
- PMID: 12833656
Item in Clipboard
Review
BMS-561392. Bristol-Myers Squibb
Curr Opin Investig Drugs.
2003 May.
Abstract
Bristol-Myers Squibb Pharma Co is developing the tumor necrosis factor-alpha (TNF alpha) converting enzyme inhibitor BMS-561392 (DPC-333) for the potential treatment of diseases characterized by overproduction of TNF alpha, such as rheumatoid arthritis (RA). A phase IIa trial in RA patients had commenced by April 2001, and by October 2002, BMS-561392 was also under investigation for the potential treatment of inflammatory bowel disease.
Similar articles
-
Drug insight: tumor necrosis factor-converting enzyme as a pharmaceutical target for rheumatoid arthritis.Nat Clin Pract Rheumatol. 2008 Jun;4(6):300-9. doi: 10.1038/ncprheum0797. Epub 2008 Apr 15. Nat Clin Pract Rheumatol. 2008. PMID: 18414459 Review.
-
Identification and characterization of 4-[[4-(2-butynyloxy)phenyl]sulfonyl]-N-hydroxy-2,2-dimethyl-(3S)thiomorpholinecarboxamide (TMI-1), a novel dual tumor necrosis factor-alpha-converting enzyme/matrix metalloprotease inhibitor for the treatment of rheumatoid arthritis.J Pharmacol Exp Ther. 2004 Apr;309(1):348-55. doi: 10.1124/jpet.103.059675. Epub 2004 Jan 12. J Pharmacol Exp Ther. 2004. PMID: 14718605
-
Characterization of (2R, 3S)-2-([[4-(2-butynyloxy)phenyl]sulfonyl]amino)-N,3-dihydroxybutanamide, a potent and selective inhibitor of TNF-alpha converting enzyme.Int Immunopharmacol. 2004 Dec 20;4(14):1845-57. doi: 10.1016/j.intimp.2004.08.003. Int Immunopharmacol. 2004. PMID: 15531300
-
Tumor necrosis factor-alpha (TNF-alpha) converting enzyme contributes to production of TNF-alpha in synovial tissues from patients with rheumatoid arthritis.J Rheumatol. 2001 Aug;28(8):1756-63. J Rheumatol. 2001. PMID: 11508576
-
[The structural features and inhibitors of tumor necrosis factor-alpha converting enzyme].Sheng Li Ke Xue Jin Zhan. 1999 Jul;30(3):245-8. Sheng Li Ke Xue Jin Zhan. 1999. PMID: 12532790 Review. Chinese. No abstract available.
Cited by
-
Inactivation of Endothelial ADAM17 Reduces Retinal Ischemia-Reperfusion Induced Neuronal and Vascular Damage.Int J Mol Sci. 2020 Jul 29;21(15):5379. doi: 10.3390/ijms21155379. Int J Mol Sci. 2020. PMID: 32751103 Free PMC article.
-
Development of predictive pharmacophore model for in silico screening, and 3D QSAR CoMFA and CoMSIA studies for lead optimization, for designing of potent tumor necrosis factor alpha converting enzyme inhibitors.J Comput Aided Mol Des. 2010 Feb;24(2):143-56. doi: 10.1007/s10822-010-9322-z. Epub 2010 Feb 24. J Comput Aided Mol Des. 2010. PMID: 20179991
-
Dynamics of ADAM17-Mediated Shedding of ACE2 Applied to Pancreatic Islets of Male db/db Mice.Endocrinology. 2015 Dec;156(12):4411-25. doi: 10.1210/en.2015-1556. Epub 2015 Oct 6. Endocrinology. 2015. PMID: 26441236 Free PMC article.
-
Enhanced axonal neuregulin-1 type-III signaling ameliorates neurophysiology and hypomyelination in a Charcot-Marie-Tooth type 1B mouse model.Hum Mol Genet. 2019 Mar 15;28(6):992-1006. doi: 10.1093/hmg/ddy411. Hum Mol Genet. 2019. PMID: 30481294 Free PMC article.
-
Immune Responses to IAV Infection and the Roles of L-Selectin and ADAM17 in Lymphocyte Homing.Pathogens. 2022 Jan 25;11(2):150. doi: 10.3390/pathogens11020150. Pathogens. 2022. PMID: 35215094 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Miscellaneous